ABCL — AbCellera Biologics Share News
0.000.00%
- $3.75bn
- $2.99bn
- $75.13m
AbCellera up on expanded antibody discovery pact with Regeneron
Brief: Abcellera Biologics Says Under Agreement, Regeneron Has Right To Develop And Commercialize Therapeutic Antibodies Resulting From Collaboration
U.S. STOCKS ON THE MOVE-Apple, MGM Resorts International, Madrigal
AbCellera rises on deal with Incyte to develop therapeutic antibodies in oncology
Brief: Abcellera Incyte Collaborate To Accelerate Discovery And Development Of Therapeutic Antibodies In Oncology
Abcellera Biologics Inc reports results for the quarter ended in June - Earnings Summary
Brief: AbCellera Q2 Revenue USD 10 Million Vs. IBES Estimate USD 12.4 Million
Brief: Abcellera Announces That The U.S. Patent Trial And Appeal Board Has Denied Berkeley Lights’ Request For Rehearing
investment in Canada
investment in Canada
Abcellera Biologics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Abcellera Reports Q1 2023 Business Results
Abcellera Biologics Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: AbCellera And RQ Bio Partner To Accelerate Advancement Of New Therapies For Infectious Disease
Brief: Abcellera Announces Two Presentations On T-Cell Engager Discovery At Aacr 2023
Brief: Abcellera Biologics Maintains Nominal Amount Of Cash With Silicon Valley Bank To Secure A Corporate Credit Card
Abcellera Biologics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Abcellera Reports Full Year 2022 Business Results
Abcellera Biologics Inc expected to post a loss of 1 cent a share - Earnings Preview